Anocca doses first patient in Sweden
Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.
October 1, 2026
The patient was treated at Karolinska University Hospital. It is one of eight university hospitals in Sweden, Denmark, Germany, and the Netherlands taking part in the multicenter VIDAR-1 study, where patient recruitment and manufacturing of the investigational therapy are ongoing. The therapy is the first in a series of TCR-T cell therapies that Anocca both develops and manufactures in Södertälje.
“As a Sweden-based company, we are very pleased to now have successfully started dosing patients in Sweden as well,” says Reagan Jarvis, co-founder and CEO of Anocca. “We are encouraged by the early signals of both safety and biological activity that we have observed in previously treated patients.”
Scaling the next generation of T-cell therapy
Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product.
“Pancreatic cancer is still one of the deadliest forms of cancer. This treatment represents a new, advanced approach for patients with pancreatic cancer, and it is still at an early stage of clinical development,” says Maximilian Kordes, consultant and pancreatic cancer specialist and lead investigator for the study at Karolinska University Hospital’s Phase 1 unit.
Published: October 1, 2026
